New positions 0
None.
Institutional investment manager (13F filer) CIK 200406Name as filed: JOHNSON & JOHNSONIts filings on EDGARAll funds
Measures activity, not value. Not investment advice.
Reported $761.7M in 13 companies we cover at the end of Q3 2026; opened 0 positions and sold out of 0; largest position: Protagonist Therapeutics, $345.1M (45% of the reported value).
Q3 2021Highest $4.4BQ3 2026
| Quarter | Reported value | Positions we cover | Filed | Report |
|---|---|---|---|---|
| Q3 2026 | $761.7M | 13 | 26 Oct 2026 | 13F-HR |
| Q2 2026 | $798.7M | 13 | 6 Aug 2026 | 13F-HR |
| Q1 2026 | $652.4M | 14 | 13 May 2026 | 13F-HR |
| Q4 2025 | $555.0M | 15 | 13 Feb 2026amended 18 Mar 2026 | 13F-HR/A |
| Q3 2025 | $503.9M | 17 | 13 Nov 2025amended 18 Mar 2026 | 13F-HR/A |
| Q2 2025 | $334.1M | 17 | 22 Jul 2025 | 13F-HR |
| Q1 2025 | $341.9M | 17 | 7 May 2025 | 13F-HR |
| Q4 2024 | $386.1M | 17 | 13 Feb 2025 | 13F-HR |
| Q3 2024 | $427.3M | 16 | 13 Nov 2024 | 13F-HR |
| Q2 2024 | $400.7M | 17 | 9 Aug 2024 | 13F-HR |
| Q1 2024 | $4.4B | 14 | 10 May 2024 | 13F-HR |
| Q4 2023 | $4.4B | 14 | 14 Feb 2024 | 13F-HR |
| Q3 2023 | $271.5M | 14 | 9 Nov 2023 | 13F-HR |
| Q2 2023 | $322.1M | 13 | 2 Aug 2023 | 13F-HR |
| Q1 2023 | $307.4M | 14 | 11 May 2023 | 13F-HR |
| Q4 2022 | $0 | 13 | 9 Feb 2023 | 13F-HR |
| Q3 2022 | $339.8M | 13 | 10 Nov 2022 | 13F-HR |
| Q2 2022 | $391.5M | 13 | 10 Aug 2022 | 13F-HR |
| Q1 2022 | $529.0M | 13 | 9 May 2022 | 13F-HR |
| Q4 2021 | $878.4M | 14 | 14 Feb 2022 | 13F-HR |
| Q3 2021 | $1.1B | 14 | 12 Nov 2021amended 16 Nov 2021 | 13F-HR/A |
| # | Company | Shares | Value | % of portfolio The position's value as a share of the reported value of the whole report. | % of company Shares held as a share of the company's shares outstanding (latest financial report). | Change vs Q2 2026 |
|---|---|---|---|---|---|---|
| 1 | Protagonist Therapeutics PTGX | 2.4M | $345.1M | 45% | 3.8% | No change |
| 2 | MeiraGTx MGTX | 6.6M | $73.1M | 9.6% | 6.8% | No change |
| 3 | Rapport Therapeutics RAPP | 1.8M | $60.0M | 7.9% | 3.0% | No change |
| 4 | Contineum Therapeutics CTNM | 2.0M | $26.6M | 3.5% | 8.6% | No change |
| 5 | Cerebras Systems CBRS | 129K | $22.9M | 3.0% | +75K140% | |
| 6 | Xencor XNCR | 748K | $18.7M | 2.5% | 1.00% | No change |
| 7 | Fate Therapeutics FATE | 3.4M | $8.0M | 1.1% | 2.8% | No change |
| 8 | CVRx CVRX | 4.0M | $7.0M | 0.92% | 14% | No change |
| 9 | PROCEPT BioRobotics PRCT | 358K | $6.5M | 0.86% | 0.62% | No change |
| 10 | Neumora Therapeutics NMRA | 1.8M | $1.1M | 0.14% | 0.98% | No change |
| 11 | Vor Biopharma VOR | 54K | $1.0M | 0.13% | 0.09% | No change |
| 12 | Standard BioTools LAB | 312K | $231K | 0.03% | 0.08% | No change |
| 13 | Adicet Bio ACET | 23K | $163K | 0.02% | 0.24% | No change |
None.
None.
| Company | Added | Shares |
|---|---|---|
| Cerebras Systems CBRS | $13.3M | +75K140% |
None.
| Sector | Q3 2026 | As a bar | Q2 2026 | Change |
|---|---|---|---|---|
| Health Care | 96% | 98% | -1.9 pts | |
| Technology | 4.0% | 2.1% | +1.9 pts |
The bar is Q3 2026; the tick marks Q2 2026.
From Form 13F: long positions in US-listed shares and options at the quarter end, filed up to 45 days later; short positions are not reported. Values are in dollars (reports filed before 2023 were in thousands and are converted). Measures activity, not value. Not investment advice.